Second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer

Benzer Materyaller

• Response to second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer: make no assumptions
  Yazar:: Karam, I., ve diğerleri
  Baskı/Yayın Bilgisi: (2012)
• Predictive factors in patients with EGFR mutation-negative non-small cell lung cancer treated with erlotinib
  Yazar:: ISHII, HIDENOBU, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients
  Yazar:: Liao, Bin-Chi, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib
  Yazar:: Costa, Daniel B., ve diğerleri
  Baskı/Yayın Bilgisi: (2008)
• Second-line treatment of non-small-cell lung cancer with wild-type EGFR status. What is the best approach?
  Yazar:: Elghissassi, Ibrahim, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)